Curr Treat Options Oncol
Chemotherapy-Induced Sarcopenia.
Bozzetti F
Sarcopenia is being consistently recognized as a condition not only associated with the presence of a malignancy but also induced by the oncologic the ...
Read More
Source: PubMed
Clin. Cancer Res. 2020 Jan 30
FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1.
Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, Tang S, Xu Y, Liu J, Fu W, Song P, King-Kallimanis BL, Hou S, Gong Y, Kalavar S, Ghosh S, Philip R, Goldberg KB, Theoret MR, Blumenthal GM, Kluetz PG, Sridhara R, Pazdur R, Beaver JA
On March 8, 2019, the FDA granted accelerated approval to atezolizumab in combination with paclitaxel protein-bound for the treatment of adult patient ...
Read More
Source: PubMed
Curr Drug Discov Technol 2020 Jan 27
Evaluation of Ficus retusa L. Leaves with special reference to Anti-diarrheal and Anti-spasmodic activity.
Khan NA, Tomar C, Shrivastav A, Ahmad A, Mishra AK
Diarrhea is considered as a major cause of mortality, especially in children and aged persons. Because of diarrhea, 17% of admitted children get die. ...
Read More
Source: PubMed
Clin. Cancer Res. 2020 Jan 28
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).
Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, Matei D, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM
The relevance of the MET/Hepatocyte Growth Factor (HGF) pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib i ...
Read More
Source: PubMed
Ann. Oncol.
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA
Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combinat ...
Read More
Source: PubMed
